1
|
Stanganelli C, Torres DC, Ortega C, Márquez ME, Remedi V, Cabrera J, Mardaraz C, Galvano C, Krzywinski A, Lang C, Zanella L, Agriello E, Bezares R, Pavlovsky A, Pavlovsky MA, Oppezzo P, Slavutsky I. Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients. Ann Hematol 2022; 101:341-348. [PMID: 34713310 DOI: 10.1007/s00277-021-04703-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 10/18/2021] [Indexed: 11/28/2022]
Abstract
Chronic lymphocytic leukemia (CLL) is the most common mature B-cell neoplasm in the West. IGHV4-34 is one of the most frequently used genes in CLL patients, which usually display an indolent outcome. In this study, we explored the mutational profile of CLL patients expressing IGHV4-34 within different stereotypes and their association with prognostic factors and clinical outcome. A multi-institutional cohort of unselected 1444 CLL patients was analyzed by RT-PCR and bidirectional sequencing. Cytogenetics and molecular cytogenetics analyses were also performed. We identified 144 (10%) IGHV4-34 expressing cases, 119 mutated (M), 44 of them with stereotyped B-cell receptors. Subset #4 was the most frequent (56.8% of cases) followed by subsets #16 (13.6%), #29 (6.8%), and #201 (2.3%), with different distribution among countries. Analysis of somatic hypermutation profile showed significant differences among stereotyped subsets for G28>D/E, P45>S, E55>Q, and S64>I changes (p < 0.01) and high frequency of disruption of the glycosylation motif in the VH CDR2 region. All stereotyped IGHV4-34 cases showed normal karyotypes. Deletion 13q14 as a sole alteration was present in 42.8% of stereotyped cases with a different distribution among subsets. A shorter time to first treatment was found in non-stereotyped vs. stereotyped M-IGHV4-34 patients (p = 0.034). Our results add new information supporting the importance of recurrent amino acid changes at particular positions, contributing to refine the molecular characterization of South American CLL patients.
Collapse
Affiliation(s)
- Carmen Stanganelli
- División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.
| | - Davi Coe Torres
- Instituto Nacional de Câncer, Río de Janeiro, RJ, Brazil
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
| | - Claudia Ortega
- Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - María Elena Márquez
- Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay
- Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela
| | - Victoria Remedi
- Hospital Maciel, Administración Servicios de Salud del Estado, Ministerio de Salud, Montevideo, Uruguay
| | - Juana Cabrera
- División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina
| | | | - Camila Galvano
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina
| | - Andrea Krzywinski
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina
| | - Cecilia Lang
- Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina
| | - Lorena Zanella
- Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina
| | | | - Raimundo Bezares
- Hospital General de Agudos Teodoro Álvarez, Buenos Aires, Argentina
| | | | | | - Pablo Oppezzo
- Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Irma Slavutsky
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina
| |
Collapse
|